Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The coronavirus disease (COVID-19) epidemic represents a major therapeutic challenge. The
highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and the long
duration of the disease have led to a massive influx of patients admitted in health services
and intensive care units. To current knowledge, there is no treatment yet that that can
prevent infection from SARS-COV-2 virus, nor the disease progression to a severe form.
Daily active smokers are rare among outpatients or hospitalized COVID-19 patients.
Several arguments suggest that nicotine could be responsible for this protective effect thank
to the nicotinic acetylcholine receptor (nAChR).
Based on epidemiological data and experimental data from scientific literature, we
hypothesize that nicotine could inhibit the penetration and spread of the virus and improve
the management of COVID19 , particularly in hospitalized patients to prevent adverse outcomes
(death, transfer to intensive care unit, care limitation, mechanical ventilation an high flow
oxygen).